CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 720 enrolled
Drug / intervention
Insulin degludec/liraglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03172494
NCT03172494Phase 3Completed
CompareCT.gov

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

Novo Nordisk A/S·interventional·Posted Jun 1, 2017·Updated Dec 14, 2022

In Brief

A Phase 3 clinical trial evaluating Insulin degludec/liraglutide, Insulin degludec, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 720 participants across 36 sites.

Detailed Summary

This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJun 1, 2017
Enrollment StartMay 26, 2017
Primary CompletionJun 14, 2019
Study CompletionJul 13, 2019
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 9.1 years ago

Interventions

Insulin degludec/liraglutidedrug

Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.

Insulin degludecdrug

Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.

Liraglutidedrug

Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.